Unleashing the Potential: Leading the Future of Biologics Market Supply

  • Exploring how FUJIFILM Diosynth Biotechnologies is taking a leading role in transforming the biomanufacturing landscape through rapid expansions and a bold network strategy
  • Highlighting cutting-edge strategies that enhance the efficiency and rapid scalability of production
  • Case study: FUJIFILM Diosynth Biotechnologies rapid expansion journey unlike anything seen before in the market
  • Focusing on people & culture: Implementing a modular cloning approach, keeping trust and delivery at the forefront, and not only rapidly scaling manufacturing capabilities across US and Europe, but also expanding to be able to flexibly meet clients’ needs end to end – covering the entire value chain
  • Prioritizing scaling responsibly both from a climate and a community perspective

Dave Stewart
SVP, Operational and Process Technology, Large Scale Business Unit
FUJIFILM Diosynth Biotechnologies

Dave Stewart, Senior Vice President Operational and Process Technology, Large-Scale Business Unit, is a proven leader in the biologics manufacturing industry, with a focus on building diverse, multi-disciplinary teams that drive customer deliverables. He brings a servant-leadership mindset and more than two decades of biotech leadership experience to cultivate accountability, collaboration and agility – assembling engaged, high-performing teams and partnerships built on trust. Dave is responsible for ensuring a consistent operations and equipment model, performance and incorporating emerging capabilities across the large-scale network at FUJIFILM Diosynth Biotechnologies (FDB) and is a key driver in building the world’s largest and most tightly connected CDMO network. Dave is passionate about transforming the biologics manufacturing industry at all scales to ensure continuous supply of critical medicines for patients. He leads a dedicated global team operating the largest end-to-end commercial manufacturing production capacity across the USA and Europe, with approximately 600,000 Liter Drug Substance Manufacturing Capacity, Drug Product capacity and Finished Goods capacity coming online in 2025. The OneFDB network serves a cross-section of global pharmaceutical and biotech industries – top 20 pharma, biotechnology leaders and startups – building strong partnerships through collaboration, and trust earned by delivering. FDB has a strong People First culture and the Large-Scale Business Unit will grow to more than 3,000 passionate people.

Dave has served in project execution, project supply and operational readiness at FDB, Holly Springs, as a site head, quality site head, and other biotech leadership positions with innovator and CDMO companies in the United States and Switzerland, and as a member of Site Leadership Team for Genentech, Oceanside while leading the Technology team. Dave served in the US Marine Corps and has a BS from Southern Illinois University, an MBA from Quantic School of Business and Technology and an MSc in Process Control from Indiana State University.